Contralateral Low-to-Intermediate Suspicion Nodule Is Not a Contraindication for Lobectomy in Patients with Papillary Thyroid Carcinoma
Authors' conclusion
Lobectomy may be a safe and feasible initial treatment option for patients with unilateral low-risk PTC and contralateral low-to-intermediate suspicious nodules.
Study context
- Population
- Patients with unilateral papillary thyroid carcinoma (PTC) who underwent lobectomy, January 2016–December 2017, Asan Medical Center, Korea1,879 nodules
- Participants
- 1,761 patients
- Exposure
- Contralateral nodules present vs absent at lobectomy
- Presentn = 700
- Absentn = 1,061reference
- Outcome
- 5-year contralateral PTC disease-free survival
- Follow-up
- 5 years
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
P = 0.003
Observational data: associations, not effects.
Further findings
- Contralateral PTC diagnosed in Present
- 2.9% · 20 of 700
- Growth of contralateral nodules (Present) · median follow-up 59 months
- 0.1 · median · range −3.4 to 4.7 cm · cm
- Growth of contralateral nodules (Present) — Median size of contralateral nodules
- 0.5 cm
- Growth of contralateral nodules (Present) — Nodules unchanged, decreased or disappeared
- 54.7%
- Growth of contralateral nodules (Present) — Nodules increased ≥0.3 cm
- 14.8%
5-year recurrence-free survival
- Did not differ significantly between Present and Absent
Safety
Permanent hypocalcemia after completion thyroidectomy
- Permanent hypocalcemia among 39 patients with completion thyroidectomy
- 2 (5.1%)
Original publication
Contralateral Low-to-Intermediate Suspicion Nodule Is Not a Contraindication for Lobectomy in Patients with Papillary Thyroid Carcinoma. Thyroid. Published 26 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →